1. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178(2):203–11.
2. Bitew, A., & Abebaw, Y. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC Women’s Health, 18(1) (2018)., N.PAG. https://doi-org.proxy1.lib.tju.edu/10.1186/s12905-018-0607-z
3. Yan, L., Wang, X., Seyedmousavi, S., Yuan, J., Abulize, P., Pan, W., . . . Deng, S. (2019). Antifungal susceptibility profile of Candida albicans isolated from vulvovaginal candidiasis in Xinjiang Province of China. Mycopathologia,1-10. doi:https://doi.org/10.1007/s11046-018-0305-2.
4. Workowski, Kimberly. “Sexually transmitted diseases treatment guidelines, 2015.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 5 June 2015, https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm.
5. Yano, J., Fidel, P. L., Fidel, P. L., Jr, Noverr, M. C., Sobel, J. D., Nyirjesy, P., … Yu, Q. (2019). Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Women’s Health, 19(1), N.PAG. https://doi-org.proxy1.lib.tju.edu/10.1186/s12905-019-0748-8